Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altana’s Omnaris Is Both Approved And “Approvable” For Allergenic Rhinitis

This article was originally published in The Pink Sheet Daily

Executive Summary

Ciclesonide nasal spray is approved in ages 12 and older, and “approvable” in ages two to 11, Altana says.

You may also be interested in...



Sepracor Plans Alvesco, Omnaris Drug Launches Following Acquisition From Nycomed

Sepracor’s 1,600-person sales force will promote the asthma and allergic rhinitis treatments.

Sepracor Plans Alvesco, Omnaris Drug Launches Following Acquisition From Nycomed

Sepracor’s 1,600-person sales force will promote the asthma and allergic rhinitis treatments.

Nycomed Seeks U.S. Partner To Promote Alvesco Asthma Inhaler And Intranasal Omnaris

FDA approved Alvesco to treat asthma in patients 12 and older Jan. 10, the Swiss pharma tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel